Navigation Links
Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide
Date:5/3/2011

-acute development program. The FDA's recent grant of Fast Track designation and Medtronic's entry into a collaboration agreement to support us in the current trial emphasize the regulatory and commercial interest in cenderitide's potential to address an important unmet medical need for heart failure patients," said Joshua Kazam, Nile's Chief Executive Officer.

About Nile Therapeutics

Nile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's plans to develop cenderitide in the post-acute setting, the anticipated benefits of cenderitide for patients in the post-acute setting, and Nile's ability to obtain FDA approval of cenderitide in the post-acute setting, are forward-looking statements. Forward-looking statements also include statements regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, expected patient enrollment, anticipated benefits of cenderitide, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management a
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014  Medical Science Liaisons serve as a ... the healthcare sector. As the impact of technology in ... how Medical Science Liaisons (MSLs) interact with physicians and ... the tablet to not only share important disease and ... thought leader interactions across geographies and therapeutic areas. ...
(Date:8/22/2014)... 22, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... instrument for any modern science laboratory as ... materials. It can be broadly classified into ...
(Date:8/22/2014)... Research and Markets ( ... the  "Global Operating Room Equipment Market 2014-2018" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,An operating room is ... a healthcare facility used to perform surgical ... equipment, which ensures patient care and enhanced ...
Breaking Medicine Technology:iPads Enhancing Medical Science Liaison Interactions with Thought Leaders, New Study Shows 2Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2
... June 13 Telmisartan, an angiotensin receptor blocker, ... been studied in clinical trials in more than 50,000 patients. ... market exposure of 34.5 million patient years. Convincing safety data ... the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which ...
... Scientists from the Barbara Ann Karmanos Cancer Institute in ... agents used to promote bone health and inhibit resorption, may ... early stage breast cancer who take them for their anti-osteoporosis ... Society of Clinical Oncology Annual Meeting. , ...
Cached Medicine Technology:Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 2Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 3Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 4Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010 5Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 2Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 3Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 4
(Date:8/22/2014)... time an oncogenic somatic mutation at amino acid 918 ... identified in small cell lung cancer (SCLC) tumors and ... produced increased intracellular signaling and cell growth. , SCLC ... 15% of all lung cancers and is strongly associated ... has been extensively examined for genomic alterations and targeted ...
(Date:8/22/2014)... Paying tuition and other related educational ... year for four nurse educators pursuing advanced degrees, thanks ... Nursing Foundation for Nursing Education . This year’s recipients ... more than in 2013, thanks to these named NLN ... Isaac Marcil Endowment Funds, both donated by Kathy Mershon; ...
(Date:8/22/2014)... 22, 2014 Testosterone treatment lawsuits ... U.S. courts on behalf of men who allegedly ... of prescription low testosterone therapies, Bernstein Liebhard LLP ... was filed against Pfizer Inc. on July 31st ... heart issues due to his use of Depo-Testosterone. ...
(Date:8/22/2014)... Hudson County, NJ (PRWEB) August 22, 2014 ... that a leading specialist in Internal Medicine, Geriatrics, ... joined the network, CarePoint Health Medical Group. Their ... of highly skilled and experienced physicians comprise CarePoint ... doctors and practices in Hudson County, representing a ...
(Date:8/22/2014)... News) -- Back-to-school time provides an opportunity for parents ... family schedules, an expert suggests. "Forget New Year,s ... also be the start of a new fitness and ... kinesiology at the University of the Sciences in Philadelphia, ... extracurricular activities likely to build up, "it,s important for ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... of the National Commission on Macroeconomics and Health, K ... to make mandatory a comprehensive Universal Health Insurance System ... of 9 % of the GDP on health and ... growth and provision of basic infrastructural needs. ,Inaugurating ...
... The FDA has sent shock waves in the industry ... Nov. 8 from the U.S. Food and Drug Administration ... for qualified health claims for lycopene, tomatoes, and tomatoes-based ... lycopene (tomatoes, tomato-based foods containing lycopene) may reduce the ...
... Millennium Development Goals Memorandum signed between 189 countries from ... better health conditions to people in poor countries have ... these people had been reported in the Journal British ... make meaningful progress on the strategy aims - the ...
... various factors which are responsible for malaria infection and ... link to difference in genetic makeup between different individuals//. ... and colleagues were interested in the relative contributions of ... malaria. To estimate the overall contribution of genetic factors ...
... claimed 10 lives while over 3,000 people were suffering ... government officer said Friday//., ,"Nearly 3,000 tribal people ... have been in the grip of malaria and typhoid. ... three days," the district's acting collector Amir Ali said ...
... in the US have discovered a hormone that regulates ... the future//. ,Researchers at Stanford University, California, looked ... that codes for ghrelin, an appetite-boosting hormone. ... same protein precursor that produced ghrelin. The researchers say ...
Cached Medicine News:Health News:Need For Social Churning Emphasized In CMC Meet On ‘Leadership In Healthcare 2Health News:Programs for development of health in poor countries not effective 2Health News:Researchers finding link between malaria susceptibility and genetic makeup 2
... Crossover system of implants and instruments provides ... posterior rod construct in the thoracic and ... system are available in three size ranges: ... can be used with the Isola, Pediatric ...
Portable ultrasound doppler system for peripheral and transcranial investigation....
Multiwindow transcranial and peripheral Doppler system....
Bi-Directional doppler volume flowmeter....
Medicine Products: